Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
41
AMRN Quote, Financials, Valuation and Earnings
Last price:
$15.72
Seasonality move
:
2.45%
Day range:
$15.42 - $16.00
52-week range:
$7.08 - $20.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.20x
P/B ratio:
0.71x
Volume:
45.7K
Avg. volume:
90.7K
1-year change:
29.78%
Market cap:
$326.8M
Revenue:
$228.7M
EPS (TTM):
-$4.17
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
$50.6M | $0.07 | 1.39% | -100% | $12.00 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
CLLS
Cellectis SA
|
$12.7M | -$0.11 | -5.7% | -56.58% | $7.25 |
|
DBVT
DBV Technologies SA
|
$1.3M | -$0.22 | -- | -86.12% | $40.29 |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.2B | $6.51 | 10.99% | 109.38% | $219.40 |
|
TRIB
Trinity Biotech Plc
|
$7.5M | -$0.57 | -33.73% | -28.57% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
$15.72 | $12.00 | $326.8M | -- | $0.00 | 0% | 8.20x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$1.25 | $17.94 | $1M | -- | $0.00 | 0% | 0.73x |
|
CLLS
Cellectis SA
|
$4.06 | $7.25 | $408.4M | -- | $0.00 | 0% | 5.05x |
|
DBVT
DBV Technologies SA
|
$20.55 | $40.29 | $1.1B | -- | $0.00 | 0% | -- |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$168.72 | $219.40 | $10.3B | 15.09x | $0.00 | 0% | 2.48x |
|
TRIB
Trinity Biotech Plc
|
$0.76 | -- | $14.1M | -- | $0.00 | 0% | 0.27x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
1.45% | 2.914 | 1.98% | 2.35x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.310 | -- | 1.20x |
|
CLLS
Cellectis SA
|
54.27% | 0.329 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.992 | 5.85% | 1.41x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.201 | 67.81% | 1.24x |
|
TRIB
Trinity Biotech Plc
|
147.47% | 0.766 | 785.94% | 0.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
$21.2M | -$1.7M | -17.51% | -17.79% | -3.42% | -$12.8M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
|
TRIB
Trinity Biotech Plc
|
$5.3M | -$2.2M | -45.03% | -- | -11.29% | -$6.3M |
Amarin Corp. Plc vs. Competitors
-
Which has Higher Returns AMRN or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of --. Amarin Corp. Plc's return on equity of -17.79% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About AMRN or BDRX?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -23.86%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 14128.11%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Amarin Corp. Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is AMRN or BDRX More Risky?
Amarin Corp. Plc has a beta of 0.839, which suggesting that the stock is 16.111% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.469%.
-
Which is a Better Dividend Stock AMRN or BDRX?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or BDRX?
Amarin Corp. Plc quarterly revenues are $49.4M, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Amarin Corp. Plc's net income of -$7.7M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 8.20x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc8.20x -- $49.4M -$7.7M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns AMRN or CLLS?
Cellectis SA has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of 1.68%. Amarin Corp. Plc's return on equity of -17.79% beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About AMRN or CLLS?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -23.86%. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 78.57%. Given that Cellectis SA has higher upside potential than Amarin Corp. Plc, analysts believe Cellectis SA is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 CLLSCellectis SA2 2 0 -
Is AMRN or CLLS More Risky?
Amarin Corp. Plc has a beta of 0.839, which suggesting that the stock is 16.111% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.833, suggesting its more volatile than the S&P 500 by 183.275%.
-
Which is a Better Dividend Stock AMRN or CLLS?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or CLLS?
Amarin Corp. Plc quarterly revenues are $49.4M, which are larger than Cellectis SA quarterly revenues of $35M. Amarin Corp. Plc's net income of -$7.7M is lower than Cellectis SA's net income of $586.4K. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 8.20x versus 5.05x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc8.20x -- $49.4M -$7.7M CLLSCellectis SA5.05x -- $35M $586.4K
-
Which has Higher Returns AMRN or DBVT?
DBV Technologies SA has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of --. Amarin Corp. Plc's return on equity of -17.79% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About AMRN or DBVT?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -23.86%. On the other hand DBV Technologies SA has an analysts' consensus of $40.29 which suggests that it could grow by 96.04%. Given that DBV Technologies SA has higher upside potential than Amarin Corp. Plc, analysts believe DBV Technologies SA is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 DBVTDBV Technologies SA4 0 1 -
Is AMRN or DBVT More Risky?
Amarin Corp. Plc has a beta of 0.839, which suggesting that the stock is 16.111% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.978, suggesting its less volatile than the S&P 500 by 197.819%.
-
Which is a Better Dividend Stock AMRN or DBVT?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or DBVT?
Amarin Corp. Plc quarterly revenues are $49.4M, which are larger than DBV Technologies SA quarterly revenues of --. Amarin Corp. Plc's net income of -$7.7M is higher than DBV Technologies SA's net income of -$33M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 8.20x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc8.20x -- $49.4M -$7.7M DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns AMRN or JAZZ?
Jazz Pharmaceuticals Plc has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of 22.33%. Amarin Corp. Plc's return on equity of -17.79% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B -
What do Analysts Say About AMRN or JAZZ?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -23.86%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $219.40 which suggests that it could grow by 30.04%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Amarin Corp. Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 JAZZJazz Pharmaceuticals Plc9 1 0 -
Is AMRN or JAZZ More Risky?
Amarin Corp. Plc has a beta of 0.839, which suggesting that the stock is 16.111% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.260, suggesting its less volatile than the S&P 500 by 73.986%.
-
Which is a Better Dividend Stock AMRN or JAZZ?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or JAZZ?
Amarin Corp. Plc quarterly revenues are $49.4M, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Amarin Corp. Plc's net income of -$7.7M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 8.20x versus 2.48x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc8.20x -- $49.4M -$7.7M JAZZJazz Pharmaceuticals Plc2.48x 15.09x $1.1B $251.4M
-
Which has Higher Returns AMRN or TRIB?
Trinity Biotech Plc has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of -31.41%. Amarin Corp. Plc's return on equity of -17.79% beat Trinity Biotech Plc's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M TRIBTrinity Biotech Plc35.03% -$0.46 $55.5M -
What do Analysts Say About AMRN or TRIB?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -23.86%. On the other hand Trinity Biotech Plc has an analysts' consensus of -- which suggests that it could grow by 1876.81%. Given that Trinity Biotech Plc has higher upside potential than Amarin Corp. Plc, analysts believe Trinity Biotech Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 TRIBTrinity Biotech Plc0 0 0 -
Is AMRN or TRIB More Risky?
Amarin Corp. Plc has a beta of 0.839, which suggesting that the stock is 16.111% less volatile than S&P 500. In comparison Trinity Biotech Plc has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.502%.
-
Which is a Better Dividend Stock AMRN or TRIB?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Trinity Biotech Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or TRIB?
Amarin Corp. Plc quarterly revenues are $49.4M, which are larger than Trinity Biotech Plc quarterly revenues of $15.2M. Amarin Corp. Plc's net income of -$7.7M is lower than Trinity Biotech Plc's net income of -$4.8M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Trinity Biotech Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 8.20x versus 0.27x for Trinity Biotech Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc8.20x -- $49.4M -$7.7M TRIBTrinity Biotech Plc0.27x -- $15.2M -$4.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 4.19% over the past day.
Sell
37
ACLS alert for Feb 20
Axcelis Technologies, Inc. [ACLS] is down 1.71% over the past day.
